JP2019514974A5 - - Google Patents

Info

Publication number

JP2019514974A5

JP2019514974A5 JP2018558238A JP2018558238A JP2019514974A5 JP 2019514974 A5 JP2019514974 A5 JP 2019514974A5 JP 2018558238 A JP2018558238 A JP 2018558238A JP 2018558238 A JP2018558238 A JP 2018558238A JP 2019514974 A5 JP2019514974 A5 JP 2019514974A5

Authority

JP

Japan

Prior art keywords

weeks

dose

vedolizumab

administered

patient

Prior art date

2017-05-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 41
• 229960000485 methotrexate Drugs 0.000 claims description 41
• 208000011231 Crohn disease Diseases 0.000 claims description 33
• 229960004914 vedolizumab Drugs 0.000 claims description 32
• 229960002964 adalimumab Drugs 0.000 claims description 28
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 21
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 12
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 12
• 238000002648 combination therapy Methods 0.000 claims description 9
• 239000003246 corticosteroid Substances 0.000 claims description 9
• 229960000598 infliximab Drugs 0.000 claims description 8
• 238000001802 infusion Methods 0.000 claims description 8
• 238000001990 intravenous administration Methods 0.000 claims description 8
• 150000001413 amino acids Chemical class 0.000 claims description 7
• 239000002955 immunomodulating agent Substances 0.000 claims description 6
• 229940121354 immunomodulator Drugs 0.000 claims description 6
• 230000002584 immunomodulator Effects 0.000 claims description 5
• 239000000427 antigen Substances 0.000 claims description 4
• 102000036639 antigens Human genes 0.000 claims description 4
• 108091007433 antigens Proteins 0.000 claims description 4
• 229960003115 certolizumab pegol Drugs 0.000 claims description 4
• 229960001743 golimumab Drugs 0.000 claims description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
• 229960004436 budesonide Drugs 0.000 claims description 2
• 229960004618 prednisone Drugs 0.000 claims description 2
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
• 238000010254 subcutaneous injection Methods 0.000 claims description 2
• 239000007929 subcutaneous injection Substances 0.000 claims description 2
• 239000000825 pharmaceutical preparation Substances 0.000 claims 19
• 239000008194 pharmaceutical composition Substances 0.000 claims 17
• 239000003814 drug Substances 0.000 claims 2
• 238000009472 formulation Methods 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• -1 SEQ ID NO: 2 amino acid Chemical class 0.000 claims 1
• 238000000034 method Methods 0.000 description 67
• 238000011295 triple combination therapy Methods 0.000 description 17
• 239000000890 drug combination Substances 0.000 description 1